Literature DB >> 10069454

Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage.

S Boulton1, S Kyle, B W Durkacz.   

Abstract

DNA-dependent protein kinase (DNA-PK) and poly(ADP-ribose) polymerase (PARP) are activated by DNA strand breaks and participate in DNA repair. We investigated the interactive effects of inhibitors of these enzymes [wortmannin (WM), which inhibits DNA-PK, and 8-hydroxy-2-methylquinazolin-4-one (NU1025), a PARP inhibitor] on cell survival and DNA double-strand break (DSB) and single-strand break (SSB) rejoining in Chinese hamster ovary-K1 cells following exposure to ionizing radiation (IR) or temozolomide. WM (20 microM) or NU1025 (300 microM) potentiated the cytotoxicity of IR with dose enhancement factors at 10% survival (DEF10) values of 4.5 +/- 0.6 and 1.7 +/- 0.2, respectively. When used in combination, a DEF10 of 7.8 +/- 1.5 was obtained. WM or NU1025 potentiated the cytotoxicity of temozolomide, and an additive effect on the DEF10 value was obtained with the combined inhibitors. Using the same inhibitor concentrations, their single and combined effects on DSB and SSB levels following IR were assessed by neutral and alkaline elution. Cells exposed to IR were post-incubated for 30 min to allow repair to occur. WM or NU1025 increased net DSB levels relative to IR alone (DSB levels of 1.29 +/- 0.04 and 1.20 +/- 0.05, respectively, compared with 1.01 +/- 0.03 for IR alone) and the combination had an additive effect. WM had no effect on SSB levels, either alone or in combination with NU1025. SSB levels were increased to 1.27 +/- 0.05 with NU1025 compared with IR alone, 1.02 +/- 0.04. The dose-dependent effects of the inhibitors on DSB levels showed that they were near maximal by 20 microM WM and 300 microM NU1025. DSB repair kinetics were studied. Both inhibitors increased net DSB levels over a 3 h time period; when they were combined, net DSB levels at 3 h were identical to DSB levels immediately post-IR. The combined use of DNA repair inhibitors may have therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10069454     DOI: 10.1093/carcin/20.2.199

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  22 in total

1.  The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Authors:  Xiaozhe Wang; David T Weaver
Journal:  Am J Cancer Res       Date:  2010-01-03       Impact factor: 6.166

Review 2.  PARP inhibitor treatment in ovarian and breast cancer.

Authors:  Marcie K Weil; Alice P Chen
Journal:  Curr Probl Cancer       Date:  2011 Jan-Feb       Impact factor: 3.187

3.  Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.

Authors:  Jie Li; Ruixin Wang; Yifan Kong; Meaghan M Broman; Colin Carlock; Long Chen; Zhiguo Li; Elia Farah; Timothy L Ratliff; Xiaoqi Liu
Journal:  Mol Cancer Ther       Date:  2017-01-09       Impact factor: 6.261

Review 4.  Coordination of DNA single strand break repair.

Authors:  Rachel Abbotts; David M Wilson
Journal:  Free Radic Biol Med       Date:  2016-11-24       Impact factor: 7.376

Review 5.  Targeting DNA repair and the cell cycle in glioblastoma.

Authors:  Brian M Alexander; Nancy Pinnell; Patrick Y Wen; Alan D'Andrea
Journal:  J Neurooncol       Date:  2011-11-24       Impact factor: 4.130

6.  Phosphorylation of p53 by TAF1 inactivates p53-dependent transcription in the DNA damage response.

Authors:  Yong Wu; Joy C Lin; Landon G Piluso; Joseph M Dhahbi; Selene Bobadilla; Stephen R Spindler; Xuan Liu
Journal:  Mol Cell       Date:  2013-11-27       Impact factor: 17.970

7.  Spermidinyl-CoA-based HAT inhibitors block DNA repair and provide cancer-specific chemo- and radiosensitization.

Authors:  Keya Bandyopadhyay; Jean-Louis Banères; Aimée Martin; Casimir Blonski; Joseph Parello; Ruth A Gjerset
Journal:  Cell Cycle       Date:  2009-09-02       Impact factor: 4.534

Review 8.  Poly(ADP-ribosyl)ation in regulation of chromatin structure and the DNA damage response.

Authors:  Michael Tallis; Rosa Morra; Eva Barkauskaite; Ivan Ahel
Journal:  Chromosoma       Date:  2013-10-27       Impact factor: 4.316

Review 9.  Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment.

Authors:  A Peralta-Leal; M I Rodríguez; F J Oliver
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

Review 10.  The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets.

Authors:  Maria José García; Javier Benítez
Journal:  Clin Transl Oncol       Date:  2008-02       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.